Business News • PR NewsWire • China CDE erteilt CMG901 die Breakthrough Therapy Designation für Claudin 18.2-Positive fortgeschrittene Magen- und Speiseröhrenkrebserkrankungen

China CDE erteilt CMG901 die Breakthrough Therapy Designation für Claudin 18.2-Positive fortgeschrittene Magen- und Speiseröhrenkrebserkrankungen

China CDE erteilt CMG901 die Breakthrough Therapy Designation für Claudin 18.2-Positive fortgeschrittene Magen- und Speiseröhrenkrebserkrankungen

CHENGDU, China, 23. September 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) gab bekannt, dass das Center for Drug Evaluation (CDE) der China National Medical Products Administration (NMPA) CMG901 die Breakthrough Therapy Designation für die Behandlung von fortgeschrittenem...

View More : https://www.prnewswire.com:443/news-releases/china-cde-erteilt-cmg901-die-breakthrough-therapy-designation-fur-claudin-1...

Releted News by prnewswire

GTN appoints regional CEO to create the Group Shared Services

SHEIN anuncia desfile Rock The Runway: SHEIN for All com coleções de outono/inverno 2022

Cathay FHC Highlights Urgent Need for Restoring Biodiversity Through Nature-Based Solutions and Pro-Nature Investments During UNGA 77 and Climate Week NYC

China CDE erteilt CMG901 die Breakthrough Therapy Designation für Claudin 18.2-Positive fortgeschrittene Magen- und Speiseröhrenkrebserkrankungen

2022 GLOBAL CITIZEN FESTIVAL CAMPAIGN CULMINATES IN $2.4 BILLION TO END EXTREME POVERTY